Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy

Fig. 5

Therapeutic Effect of H-Zt/g4-MMAE on xenograft tumors mediated by PDAC stem-like cells and primary PDX cells: (a) Effect of H-Zt/g4-MMAE on PDAC stem-like cell derived xenografts: Athymic nude mice (five mice per group) were subcutaneously inoculated with 5 × 105 PSC+ 24/44/ESA prepared from BxPc-3, FG, and L3.6pl cells. H-Zt/g4-MMAE at 20 mg/kg was injected through tail vein in the Q12 × 2 regimen after tumors volumes reached to ~ 150 mm3. Mice injected with CmIgG-MMAE at 20 mg/kg were used as the control. (b) The eradicating effect of H-Zt/g4-MMAE on PDAC stem-like cell derived xenografts. Tumors were collected from mice as described in Fig. 4b. Tumor weight, count, and calculation were performed as described in Fig. 4b. (c) Mice were injected with individual primary PDX cell lines at 5 × 106 cells in 0.1 ml in PBS. H-Zt/g4-MMAE at 10 mg/kg was injected through tail vein in the Q12 × 2 regimen after tumors volumes reached to 150 to 200 mm3. Mice injected with CmIgG-MMAE at 10 mg/kg were used as the control. (d) Individual tumors were collected from each group of mice as described in Fig. 4b. Average tumor weight and number per group were measured to determine levels of inhibition and eradication

Back to article page